CONTACT

+91 80 2808 2808

ContactUs.BBL@biocon.com

Press Releases 2022

Biocon Biologics / News – Posts / Press Releases / Press Releases 2022

Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’

Thu, 22-Dec-2022
Posted by: Biocon Biologics

Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited

Mon, 05-Dec-2022
Posted by: Biocon Biologics

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business

Tue, 29-Nov-2022
Posted by: Biocon Biologics

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%

Tue, 15-Nov-2022
Posted by: Biocon Biologics

Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022

Fri, 11-Nov-2022
Posted by: Biocon Biologics

Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine

Fri, 04-Nov-2022
Posted by: Biocon Biologics

Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility

Fri, 05-Aug-2022
Posted by: Biocon Biologics

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%

Wed, 27-Jul-2022
Posted by: Biocon Biologics

University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre

Thu, 09-Jun-2022
Posted by: Biocon Biologics

Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada

Thu, 19-May-2022
Posted by: Biocon Biologics

1
2